RBC Transfusions Commonly Lead to Hyperkalemia, Hospitalization in CKD
Use of intravenous iron and ESAs was low among patients with stage 3 to 5 CKD.
Diagnosis & Disease Information
Upper GI Erosions Are the Most Frequent Non-CV Events in the Dialysis Population
The rate of esophageal and gastric erosions among patients on dialysis eligible for anemia treatment was approximately 49 events per 100 patient-years, investigators report.
Red Blood Cell Transfusion Rate Highest With Persistent ESA Hyporesponse
Patients receiving peritoneal dialysis rather than hemodialysis or both modalities have the lowest rate of ESA hyporesponse.
ESA Hyporesponse Tied to Adverse Events in Dialysis Population
Patients with persistent ESA hyporesponse had especially high rates of adverse events.
New Questionnaire Captures Symptoms, Burden of CKD Anemia
The new tool goes beyond hemoglobin measurement to include the effects of anemia on patients’ quality of life.
Vadadustat Noninferior to Long-Acting ESA for Anemia in Hemodialysis Patients
Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor.
FDA Approves Oral Daprodustat to Treat Anemia in Dialysis
The FDA approval of daprodustat is based on results from the ASCEND-D trial comparing daprodustat with ESAs.
Anemia Prevalence, Burden Characterized
In both men and women, the prevalence of severe anemia increased as kidney function decreased.
What Do We Know About Cancer Risk in Patients With Anemia?
Patients with anemia may know some of the risks associated with the condition, but do they know about potential cancer-related risks? How can health care professionals educate patients on the risks, and what is known about the potential association between newly diagnosed anemia and cancer risk?
HIF-PHIs and ESAs Have Comparable Adverse Effects
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
- Loading...
Loading...
Next post in Anemia
Loading... 
Loading...